Introduction Diabetes is an increasingly prevalent disorder affecting nearly 1-in-5 adults, of
which half will experience diabetic peripheral neuropathy (DPN) and a quarter will suffer …

Treatment of painful diabetic peripheral neuropathy (PDPN) is challenging and often limited
by drug tolerability and adverse effects. This review article focuses on the high-dose (8%) …

This 12-week study evaluated the efficacy and safety of capsaicin 8% patch versus placebo
patch in painful diabetic peripheral neuropathy (PDPN). Patients aged 18 years or older with …

Aims Diabetic peripheral neuropathy affects up to 60% of individuals and often leads to foot
ulceration and eventual amputation. When oral therapy has failed to achieve pain relief, the …

Purpose A network meta-analysis (NMA) was performed, aiming to assess the relative
efficacy and tolerability of the capsaicin 179-mg (8% weight for weight) cutaneous patch …

Background This 52-week study evaluated the long-term safety and tolerability of capsaicin
8% w/w (179 mg) patch repeat treatment plus standard of care (SOC) versus SOC alone in …

Introduction Current oral treatments for pain in diabetic peripheral neuropathy (DPN) do not
affect the progression of DPN ie,“disease modification.” We assessed whether Capsaicin 8 …

The adhesive capsaicin dermal patch (Qutenza®) delivers a high concentration (8% w/w) of
synthetic capsaicin, a highly selective agonist of transient receptor potential vanilloid-1 …

Diabetic neuropathy is a risk factor for developing complications such as autonomic
cardiovascular disease, osteoarthropathy, foot ulcers, and infections, which may be the …

The capsaicin 8% patch is licensed in Europe for the treatment of peripheral neuropathic
pain in nondiabetic adults. In controlled trials it provided pain relief for up to 3 months with a …